DDInter1168 DDInter1747
Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus.
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Methdilazine {u} (Compound) resembles {v} (Compound) Thioproperazine
Methdilazine {u} (Compound) resembles {v} (Compound) Epinastine
Methdilazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cyproheptadine
Methdilazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promethazine
Methdilazine {u} (Compound) binds {v} (Gene) HRH1
Methdilazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium hydroxide
Methdilazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sucralfate
Methdilazine {u} may lead to a major life threatening interaction when taken with {v} Dextropropoxyphene
Methdilazine {u} may lead to a major life threatening interaction when taken with {v} Deutetrabenazine
Methdilazine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Perphenazine
Methdilazine (Compound) resembles Thioproperazine (Compound)
Methdilazine (Compound) resembles Epinastine (Compound)
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Methdilazine (Compound) binds HRH1 (Gene)
Methdilazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Methdilazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate
Methdilazine may lead to a major life threatening interaction when taken with Dextropropoxyphene
Methdilazine may lead to a major life threatening interaction when taken with Deutetrabenazine
Methdilazine (Compound) resembles Perphenazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine